Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
383.6 DKK | -1.29% | -1.26% | +3.37% |
Apr. 30 | Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023 | CI |
Apr. 08 | Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.61 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.37% | 25.88B | B+ | ||
-6.69% | 4.13B | - | C+ | |
+11.09% | 1.72B | C+ | ||
-18.40% | 583M | - | ||
-17.62% | 429M | - | - | |
-81.65% | 216M | - | - | |
-12.38% | 113M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NSIS B Stock
- Ratings Novonesis A/S